Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.22)
# 1,407
Out of 5,000 analysts
80
Total ratings
47.1%
Success rate
16.5%
Average return
Main Sectors:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DY Dycom Industries | Initiated: Buy | $476 | $280.94 | +69.43% | 1 | Sep 24, 2026 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | n/a | $21.07 | - | 1 | Aug 24, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $100 | $33.05 | +202.57% | 12 | Aug 10, 2026 | |
| NVAX Novavax | Reiterated: Buy | $18 | $10.55 | +70.62% | 3 | Aug 6, 2026 | |
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $12.94 | +207.19% | 1 | Jun 29, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $220 → $272 | $193.45 | +40.60% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $2.02 | - | 3 | Apr 15, 2026 | |
| RZLT Rezolute | Reiterated: Hold | n/a | $4.00 | - | 6 | Mar 25, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $43 | $42.13 | +2.07% | 1 | Mar 11, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $2.51 | - | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $93.39 | n/a | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.72 | n/a | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.5668 | n/a | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $57.92 | n/a | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.30 | n/a | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.87 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.13 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $2.87 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.31 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $8.18 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.24 | n/a | 3 | Jun 23, 2023 |
Dycom Industries
Sep 24, 2026
Initiated: Buy
Price Target: $476
Current: $280.94
Upside: +69.43%
Nuvectis Pharma
Aug 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $21.07
Upside: -
Vera Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $100
Current: $33.05
Upside: +202.57%
Novavax
Aug 6, 2026
Reiterated: Buy
Price Target: $18
Current: $10.55
Upside: +70.62%
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $12.94
Upside: +207.19%
Axsome Therapeutics
May 4, 2026
Reiterated: Buy
Price Target: $220 → $272
Current: $193.45
Upside: +40.60%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $2.02
Upside: -
Rezolute
Mar 25, 2026
Reiterated: Hold
Price Target: n/a
Current: $4.00
Upside: -
Alkermes
Mar 11, 2026
Reiterated: Buy
Price Target: $43
Current: $42.13
Upside: +2.07%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.51
Upside: -
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $93.39
Upside: n/a
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.72
Upside: n/a
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.5668
Upside: n/a
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $57.92
Upside: n/a
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $13.30
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.87
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.13
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.87
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.31
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $8.18
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $24.24
Upside: n/a